Status:
COMPLETED
Forxiga CKD Japan Post-Marketing Surveillance (PMS)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
Brief Summary
To capture safety when Forxige is administrated to CKD patients in the real world setting
Detailed Description
The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch for treatment of CKD. 1. ADRs whic...
Eligibility Criteria
Inclusion
- Patients with CKD except for dialysis and/or renal failure chronic
Exclusion
- None
Key Trial Info
Start Date :
April 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 8 2024
Estimated Enrollment :
1029 Patients enrolled
Trial Details
Trial ID
NCT05306210
Start Date
April 12 2022
End Date
October 8 2024
Last Update
October 9 2025
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aichi, Japan
2
Research Site
Akita, Japan
3
Research Site
Aomori, Japan
4
Research Site
Chiba, Japan